Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:41:01 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



Q:ABUS - ARBUTUS BIOPHARMA CORP - http://www.arbutusbio.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABUS - Q5.82.65·2.751.92.71+0.031.1683.61,7072,2862.71  2.85  2.703.29  1.6917:39:56May 0215 min RT 2¢

Recent Trades - Last 10 of 2286
Time ETExPriceChangeVolume
17:39:56Q2.700.025
16:53:39Q2.63-0.0522
16:02:00Q2.710.03163
16:01:43Q2.710.034,534
16:01:36Q2.710.03290
16:00:07Q2.710.031,486
16:00:07Q2.710.03158
16:00:01Q2.710.03157
16:00:01Q2.710.03100
16:00:01Q2.710.031,230

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 17:42U:ABUSSEDAR Interim MD & ASEDAR Interim MD & A
2024-05-02 17:21U:ABUSSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-05-02 07:30U:ABUSNews ReleaseArbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-02 07:25U:ABUSNews ReleaseArbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
2024-04-18 07:30U:ABUSNews ReleaseArbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
2024-04-04 08:31U:ABUSNews ReleaseArbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
2024-03-08 07:30U:ABUSNews ReleaseArbutus to Participate in Two Upcoming Investor Conferences
2024-03-06 13:11U:ABUSSEDAR MD & ASEDAR Annual Report
2024-03-06 12:36U:ABUSSEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-02-29 07:30U:ABUSNews ReleaseArbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2024-02-15 07:30U:ABUSNews ReleaseArbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
2024-01-08 07:30U:ABUSNews ReleaseArbutus Announces 2024 Corporate Objectives and Provides Financial Update
2023-11-09 16:25U:ABUSNews ReleaseBarinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
2023-11-09 16:01U:ABUSNews ReleaseArbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting ‚ ®
2023-11-08 07:30U:ABUSNews ReleaseArbutus to Present at Jefferies London Healthcare Conference
2023-11-07 18:16U:ABUSSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-07 18:12U:ABUSSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-07 07:30U:ABUSNews ReleaseArbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-07 07:15U:ABUSNews ReleaseArbutus Announces CEO, William Collier, to Retire December 31, 2023
2023-10-24 07:30U:ABUSNews ReleaseArbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update